Cell-based Assay Market

Cell-based Assay Market Insights 2030:

The global cell-based assay market size was valued $11,744 million in 2020 and expected to reach $26,348 million by 2030, with a CAGR of 8.2% from 2021 to 2030. Cell-based assays are viable experimental instruments in life sciences and bio manufacturing. The principle of cell-based assay is based on cell culture procedures, in which living cells are produced in in-vitro and used as model systems for evaluating the biochemistry and physiology of both, healthy and sick cells.

The covid-19 pandemic has had a positive impact on the cell based assay market. This was due to rise in use of cell-based assay in COVID-19 vaccine related research in pharmaceutical and biotechnological firms.

The cell-based assays are used to show a cell's viability, proliferation, cytotoxicity, senescence, and death rate. These assays rely on reporter gene assays, which have a high sensitivity due to signal amplification of cell-signaling cascades and are hence suited for cell-signaling cascade analysis. Cell-based assays are commonly used in high-throughput screening (HTS) formats. Various public and corporate entities have increased their R&D funding to discover better and safer pharmaceuticals. Furthermore, advances in cell-based assay technology have allowed researchers to use this method for drug discovery and toxicology studies. 

The growth of cell-based assay market is driven by factors, such as rise in demand for cell-based assays in drug discovery, higher financing for cell-based research, and increase in the number of drug discovery companies.

Because of the rise in cell-based applications in drug discovery and technological advancements in cell-based assay techniques, the demand for cell-based assays has expanded dramatically in recent years. Another important factor that drives market expansion is the increase in prevalence of lifestyle disorders, such as arthritis, diabetes, epilepsy, cancer, cardiovascular diseases, and others, which still have significant unmet needs and have prompted continued R&D investments. This market is also being driven by an increase in the usage of cell-based assay techniques for high throughput screening methods, such as toxicity studies, drug screening, in-vitro testing, and others. In addition, the market is being fueled by the adoption of high-throughput screening methodologies and an increase in R&D spending. However, the exorbitant costs of these tests, as well as a scarcity of competent professionals, are impeding their expansion. Furthermore, the growing popularity of label-free cell-based assays, as well as untapped potential in developing nations, present considerable prospects for market participants.

Impact Of Covid-19 On Cell-based Assay Market (Pre And Post Analysis)

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 as a pandemic and general wellbeing crisis of international concern. COVID-19 has impacted around 210 countries across the globe. Because of the COVID-19 pandemic, state-run administrations across the globe declared inescapable lockdowns as well as friendly distancing measures to forestall breakdown of the healthcare structure. States have additionally given constraints and preventions on undertakings and elective surgeries. These obstructions continue to influence the growth of different industries, and the enhanced response towards these regulations effect the industry. The scattering, production, and store network have been impacted, because of the execution of lockdown across the globe.

Similarly, the cell-based assay market was also impacted during the pandemic. According to the WHO, COVID-19 has been confirmed in 96,012,792 people, with 2,075,870 deaths (as of January 22, 2021). Companies have increased their R&D efforts to produce a vaccine and medications to combat the SARS-CoV-2 virus as a result of the pandemic. Vaccine-related research in pharmaceutical and biotechnological firms, research centers, and academic research institutes is regarded critical, and operations and output have been largely unaffected. Both, the availability of research funding and the demand for and manufacturing of cell-based test products are predicted to expand as a result of the increase in research activities. The industry's participants are modifying their long- and short-term growth strategies to capitalize on opportunities in the research market by introducing innovative goods to combat the pandemic. For both, researchers and laboratories, the rise in need for COVID-19 research has provided a wide scope for cell-based 45 tests in viral infection research, vaccine development, and overall drug discovery.

A variety of COVID-19 vaccines or antiviral medications have been approved or are in development, and patients are now being treated symptomatically. The functional efficiency of the antibodies produced to neutralize the target virus is assessed for both, vaccinations and treatments. To reduce the time and boost the throughput of these experiments, cell-based assays are used. As a result, the demand for cell-based assays to provide an early indication of the symptoms in patients has increased. Thus, the final impact of COVID-19 on cell-based assay markets is positive.

Cell-based Assay Market Segmentation  

The cell-based assay market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is fragmented into consumable, instrument, service, and software. The consumable segment includes reagents, microplates, probes & labels, assay kits, cell lines, and others. Assay kits are further sub-divided into reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. Likewise, the cell lines are divided into immortalized cell lines, primary cell lines, and stem cell lines. 

By application, the cell-based assay market is classified into drug discovery, basic research, absorption, distribution, metabolism, & excretion (ADME) studies, predictive toxicology, and others. On the basis of end user, it is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. By region, it is bifurcated into North America, Europe, Asia-Pacific, and LAMEA.

Product Type Segment Review

By product and service type, the cell-based assay market is segmented into consumables, instruments & software, and services. Consumables dominated the market in 2019 due to largest share, which is attributed to the extensive use and repeated purchase of consumables by pharmaceutical and biopharmaceutical companies and the rise in number of preliminary studies for the development of therapeutics.

Application Type Segment Review

By application type, the cell-based assay market is categorized into drug discovery, basic research, and other applications. The drug discovery application segment dominated the market in 2020 due to the largest share which can be attributed to increasing R&D investments, technological innovations in supportive processes, the introduction of new drugs, and the growing number of CROs providing drug discovery services.

End User Segment Review 

By end users, the cell-based assay market is segmented into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. Pharmaceutical & biotechnology companies dominated the market in 2019 due to the largest share that is attributed to the increase in R&D expenditure, rise in number of drug discovery projects, and the adoption of strategic approaches such as collaborations to develop drug candidates.

By Region Segment Review

By region type, in 2019 North America accounted for the largest share of the cell-based assays market, followed by Europe. The large share of the North American regional segment can be attributed to the availability of government and private funding for life science research, the growing penetration of CROs, comprehensive drug development regulations, and the rapid adoption of advanced technologies in the region.

Major key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., Cell Signaling Technology, Inc., and Promega Corporation. The other prominent players in the value chain include Macrogen, Inc., New England Biolabs, Inc., Cisbio Bioassays, Cell Biolabs, Inc., and DiscoverX Corporation

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the cell-based assay market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers cell-based assay market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global cell-based assay market growth.

 Cell-based Assay Market Report Highlights